User login
What Is Your Diagnosis? Periungual Squamous Cell Carcinoma
Linear Unilateral Basal Cell Nevus: A Benign Follicular Hamartoma Simulating Multiple Basal Cell Carcinomas
Resolution of Tinea Pedis With Imiquimod Cream 5% in a Patient With Nodular Basal Cell Carcinoma
Hereditary Basaloid Follicular Hamartoma Syndrome
Basaloid follicular hamartoma (BFH) is a benign adnexal tumor consisting of basaloid cells with follicular differentiation. BFH can occur as a solitary lesion, multiple lesions, or an autosomal dominant inherited syndrome—BFH syndrome (BFHS).1 In patients with BFHS, adnexal tumors predominantly occur on the head, neck, and torso. The syndrome often has coexisting hypotrichosis, hypohidrosis, and palmar/plantar pitting.1 A familial presentation of BFHS with palmar pitting is discussed with a review of BFHS, including the differential diagnosis of palmar pitting.
Case Report
A 67-year-old white woman presented to dermatology with a 20-year history of several lesions on her face that started as flesh-colored papules and progressively darkened. Most lesions were 3 to 6 mm and located symmetrically around the nose, mouth, chin, and eyes. The woman presented with her 39-year-old daughter, who had a 2-year history of similar lesions around her eyes, none in a perioral distribution. The women reported that when the mother's lesions first appeared, they had the same appearance as the daughter's lesions. The persistent lesions were otherwise asymptomatic. Review of systems for both the mother and daughter were negative for other cutaneous lesions and for systemic symptoms such as fever; weight loss; and cardiovascular, respiratory, gastrointestinal, and genitourinary symptoms. The mother's medical history was significant for hypertension, diabetes mellitus, hypothyroidism, and hypercholesterolemia. The daughter's medical history was significant only for diabetes mellitus. Results of a physical examination of the mother revealed hundreds of soft flesh-colored to hyperpigmented papules, most less than 6 mm in diameter. The papules coalesced in the perioral distribution (Figure 1). Results of a physical examination of the daughter revealed similar symmetric distribution of small (most 1–2 mm but all <6 mm in diameter) flesh-colored papules in bilateral nasolabial and periorbital areas. Symmetric palmar pitting was present in both women (Figure 2). The patients had no other clinical manifestations such as frontoparietal bossing, high arched palates, jaw cysts, short fourth metacarpals, ocular hypertelorism, or narrow sloping shoulders to suggest nevoid basal cell carcinoma syndrome (NBCS). Histopathology results of both the mother and daughter revealed adnexal proliferation with follicular differentiation consistent with BFH (Figures 3–5).
Comment
BFH is a rare benign adnexal tumor that exhibits protean clinical manifestations. Despite the polymorphic clinical presentations, lesions exhibit similar histologic appearance, with only small variations.1,2 Lesions exist in both solitary and multiple forms.1-4 Multiple forms generally exhibit autosomal dominant inheritance, while solitary forms usually are not inherited.3 The solitary noninherited forms are more common than the multiple autosomal dominant inherited forms.3,5
Most reported solitary cases of BFH are in women, aged 20 to 88 years (median, 66 years; mean, 63 years).3 Patients with multiple familial disease may exhibit associated systemic diseases, though systemic disease is less likely in patients with solitary lesions.2,3 Systemic diseases that may be associated with BFHS include hypertension, cardiovascular disease, renal disease, obesity, carpal tunnel syndrome, and cancer of the breast and stomach.6 Generalized lesions also have been associated with cystic fibrosis,7 systemic lupus erythematosus,8 and myasthenia gravis.9
BFHS lesions have a predilection for the face and scalp but also have been reported on the neck, axillae, shoulders, and pubic regions.4 Wheeler et al6 examined 18 members in one family and found that dominantly-inherited generalized BFHS exhibits variability of disease. The patients exhibited lesions that ranged from hundreds of pigmented papules with associated hypotrichosis and palmar/ plantar pitting to minimal facial papules and a few milia involving only the face.6 Most papules are 1 to 2 mm.3 In mild forms, the lesions may go unnoticed or may be mistaken as normal.6 Lesions also may be present at birth or may develop in early childhood.6,10-12
Findings on physical examination most commonly associated with BFHS include milialike papules, comedonal-like papules, hypotrichosis, hypohidrosis, and palmar/plantar pitting (Table).6 Less common associated findings include atopic dermatitis, keratosis pilaris, lichen striatus, acrochordons, acanthosis nigricans—like changes, dermatosis papulosa nigra, acne vulgaris, café au lait spots, punctate palmar keratosis, and steatocystoma multiplex.6
The differential diagnoses of multiple facial papules include angiofibromas (tuberous sclerosis), multiple trichilemmomas (Cowden disease), multiple trichoepitheliomas, multiple syringomas, steatocystoma multiplex, seborrheic keratosis, melanocytic nevi, sebaceous hyperplasia, and NBCS or Gorlin syndrome.3 NBCS is believed to be caused by a lack of human homoloque patched (PTCH) tumor suppressor gene function, whereas BFHS is reported to be caused by a decrease in PTCH function.13 Girardi et al10 suggested that familial BFHS possibly is a forme fruste of NBCS (ie, since both entities involve the PTCH gene protein product or some member of its pathway).
Histologically, branching cords and thin strands of undifferentiated and anastomosing basaloid proliferations, which are surrounded by a loosely fibroblastic stroma, identify BFH.1 This histologic pattern may be found in a wide spectrum of clinically nevoid presentations, and individual lesions may be indistinguishable from infundibulocystic basal cell carcinoma (BCC). Occasional peripheral pallisading, papillary mesenchymal bodies, and connections to the epidermis also have been described.1
BFH is categorized within the spectrum of basaloid epithelial neoplasms associated with dysregulation of the PTCH signaling pathway.13 However, in general, BFH lesions show less mitotic figures and necrosis when compared with BCC.6,13 Immunohistochemistry results show CD34+ stromal cells in peritumoral distribution, resembling trichoepithelioma and distinguishing the condition from BCC, which lacks CD34 expression.14 Additional factors that distinguish BFH from BCC include BFH’s low proliferative index (ie, low Ki-67) and lack of bcl-2 expression.13,14
BFHS is a rare entity. It is a mainly histologic diagnosis with varied clinical presentations.6 Prognosis is good and treatment usually is cosmetic with shave, curette, or scissor methods most frequently reported.3 Because of the benign nature of this follicular tumor, observation without treatment is an option. It is important to be able to recognize this disease to avoid overaggressive surgical management and to closely monitor for any new tumors that may develop in these lesions.1 Monitoring and close follow-up of these lesions is necessary because some believe that familial BFHS is possibly a forme fruste of NBCS. Any indications of malignant changes in these lesions (eg, nonhealing and bleeding lesions, biopsy suggestive of BCC or other skin cancer) warrant surgical therapy. If lesions do not indicate malignant change, however, they may be removed for cosmetic reasons, but aggressive surgery, such as Mohs micrographic surgery, may put the patient at risk for unnecessary infection and increased morbidity.1
- Nelson BR, Johnson TM, Waldinger T, et al. Basaloid follicular hamartoma: a histologic diagnosis with diverse clinical presentations. Arch Dermatol. 1993;129:915-917.
- Mehregan AH, Baker S. Basaloid follicular hamartoma: three cases with localized and systematized unilateral lesions. J Cutan Pathol. 1985;12:55-65.
- Brownstein MH. Basaloid follicular hamartoma: solitary and multiple types. J Am Acad Dermatol. 1992;27: 237-240.
- Walsh N, Ackerman AB. Basaloid follicular hamartoma. J Am Acad Dermatol. 1993;29:125-127.
- Ricks M, Elston DM, Sartori CR. Multiple basaloid follicular hamartomas associated with acrochordons, seborrheic keratoses, and chondrosarcoma. Br J Dermatol. 2002;146:1068-1070.
- Wheeler CE, Carroll MA, Groben PA, et al. Autosomal dominantly inherited generalized basaloid follicular hamartoma syndrome: report of a new disease in a North Carolina family. J Am Acad Dermatol. 2000;43:189-206.
- Mascaro JM, Ferrando J, Bombi JA, et al. Congenital generalized follicular hamartoma associated with alopecia and cystic fibrosis in three siblings. Arch Dermatol. 1995;131:454-458.
- Morton S, Stevens A, Powell RJ. Basaloid follicular hamartoma, total body hair loss and SLE. Lupus. 1998;7:207-209.
- Weltfriend S, David M, Ginzburg A, et al. Generalized hair follicle hamartoma: the third case report in association with myasthenia gravis. Am J Dermatopathol. 1987;9:428-432.
- Girardi M, Federman GL, McNiff JM. Familial multiple basaloid follicular hamartomas: a report of two affected sisters. Pediatr Dermatol. 1999;16:281-284.
- Metry D, Guill C. Generalized basaloid follicular hamartoma syndrome. J Am Acad Dermatol. 2001;45:644-645.
- Keough GC, Pierson JC, McCollough ML. A congenital pink plaque. Arch Dermatol. 1997;133:381-382, 384-385.
- Jih DM, Shapiro M, James WD, et al. Familial basaloid follicular hamartoma: lesional characterization and review of the literature. Am J Dermatopathol. 2003;25:130-137.
- Naeyaert JM, Pauwels C, Geerts ML, et al. CD-34 and Ki-67 staining patterns of basaloid follicular hamartoma are different from those in fibroepithelioma of Pinkus and other variants of basal cell carcinoma. J Cutan Pathol. 2001;28:538-541.
Basaloid follicular hamartoma (BFH) is a benign adnexal tumor consisting of basaloid cells with follicular differentiation. BFH can occur as a solitary lesion, multiple lesions, or an autosomal dominant inherited syndrome—BFH syndrome (BFHS).1 In patients with BFHS, adnexal tumors predominantly occur on the head, neck, and torso. The syndrome often has coexisting hypotrichosis, hypohidrosis, and palmar/plantar pitting.1 A familial presentation of BFHS with palmar pitting is discussed with a review of BFHS, including the differential diagnosis of palmar pitting.
Case Report
A 67-year-old white woman presented to dermatology with a 20-year history of several lesions on her face that started as flesh-colored papules and progressively darkened. Most lesions were 3 to 6 mm and located symmetrically around the nose, mouth, chin, and eyes. The woman presented with her 39-year-old daughter, who had a 2-year history of similar lesions around her eyes, none in a perioral distribution. The women reported that when the mother's lesions first appeared, they had the same appearance as the daughter's lesions. The persistent lesions were otherwise asymptomatic. Review of systems for both the mother and daughter were negative for other cutaneous lesions and for systemic symptoms such as fever; weight loss; and cardiovascular, respiratory, gastrointestinal, and genitourinary symptoms. The mother's medical history was significant for hypertension, diabetes mellitus, hypothyroidism, and hypercholesterolemia. The daughter's medical history was significant only for diabetes mellitus. Results of a physical examination of the mother revealed hundreds of soft flesh-colored to hyperpigmented papules, most less than 6 mm in diameter. The papules coalesced in the perioral distribution (Figure 1). Results of a physical examination of the daughter revealed similar symmetric distribution of small (most 1–2 mm but all <6 mm in diameter) flesh-colored papules in bilateral nasolabial and periorbital areas. Symmetric palmar pitting was present in both women (Figure 2). The patients had no other clinical manifestations such as frontoparietal bossing, high arched palates, jaw cysts, short fourth metacarpals, ocular hypertelorism, or narrow sloping shoulders to suggest nevoid basal cell carcinoma syndrome (NBCS). Histopathology results of both the mother and daughter revealed adnexal proliferation with follicular differentiation consistent with BFH (Figures 3–5).
Comment
BFH is a rare benign adnexal tumor that exhibits protean clinical manifestations. Despite the polymorphic clinical presentations, lesions exhibit similar histologic appearance, with only small variations.1,2 Lesions exist in both solitary and multiple forms.1-4 Multiple forms generally exhibit autosomal dominant inheritance, while solitary forms usually are not inherited.3 The solitary noninherited forms are more common than the multiple autosomal dominant inherited forms.3,5
Most reported solitary cases of BFH are in women, aged 20 to 88 years (median, 66 years; mean, 63 years).3 Patients with multiple familial disease may exhibit associated systemic diseases, though systemic disease is less likely in patients with solitary lesions.2,3 Systemic diseases that may be associated with BFHS include hypertension, cardiovascular disease, renal disease, obesity, carpal tunnel syndrome, and cancer of the breast and stomach.6 Generalized lesions also have been associated with cystic fibrosis,7 systemic lupus erythematosus,8 and myasthenia gravis.9
BFHS lesions have a predilection for the face and scalp but also have been reported on the neck, axillae, shoulders, and pubic regions.4 Wheeler et al6 examined 18 members in one family and found that dominantly-inherited generalized BFHS exhibits variability of disease. The patients exhibited lesions that ranged from hundreds of pigmented papules with associated hypotrichosis and palmar/ plantar pitting to minimal facial papules and a few milia involving only the face.6 Most papules are 1 to 2 mm.3 In mild forms, the lesions may go unnoticed or may be mistaken as normal.6 Lesions also may be present at birth or may develop in early childhood.6,10-12
Findings on physical examination most commonly associated with BFHS include milialike papules, comedonal-like papules, hypotrichosis, hypohidrosis, and palmar/plantar pitting (Table).6 Less common associated findings include atopic dermatitis, keratosis pilaris, lichen striatus, acrochordons, acanthosis nigricans—like changes, dermatosis papulosa nigra, acne vulgaris, café au lait spots, punctate palmar keratosis, and steatocystoma multiplex.6
The differential diagnoses of multiple facial papules include angiofibromas (tuberous sclerosis), multiple trichilemmomas (Cowden disease), multiple trichoepitheliomas, multiple syringomas, steatocystoma multiplex, seborrheic keratosis, melanocytic nevi, sebaceous hyperplasia, and NBCS or Gorlin syndrome.3 NBCS is believed to be caused by a lack of human homoloque patched (PTCH) tumor suppressor gene function, whereas BFHS is reported to be caused by a decrease in PTCH function.13 Girardi et al10 suggested that familial BFHS possibly is a forme fruste of NBCS (ie, since both entities involve the PTCH gene protein product or some member of its pathway).
Histologically, branching cords and thin strands of undifferentiated and anastomosing basaloid proliferations, which are surrounded by a loosely fibroblastic stroma, identify BFH.1 This histologic pattern may be found in a wide spectrum of clinically nevoid presentations, and individual lesions may be indistinguishable from infundibulocystic basal cell carcinoma (BCC). Occasional peripheral pallisading, papillary mesenchymal bodies, and connections to the epidermis also have been described.1
BFH is categorized within the spectrum of basaloid epithelial neoplasms associated with dysregulation of the PTCH signaling pathway.13 However, in general, BFH lesions show less mitotic figures and necrosis when compared with BCC.6,13 Immunohistochemistry results show CD34+ stromal cells in peritumoral distribution, resembling trichoepithelioma and distinguishing the condition from BCC, which lacks CD34 expression.14 Additional factors that distinguish BFH from BCC include BFH’s low proliferative index (ie, low Ki-67) and lack of bcl-2 expression.13,14
BFHS is a rare entity. It is a mainly histologic diagnosis with varied clinical presentations.6 Prognosis is good and treatment usually is cosmetic with shave, curette, or scissor methods most frequently reported.3 Because of the benign nature of this follicular tumor, observation without treatment is an option. It is important to be able to recognize this disease to avoid overaggressive surgical management and to closely monitor for any new tumors that may develop in these lesions.1 Monitoring and close follow-up of these lesions is necessary because some believe that familial BFHS is possibly a forme fruste of NBCS. Any indications of malignant changes in these lesions (eg, nonhealing and bleeding lesions, biopsy suggestive of BCC or other skin cancer) warrant surgical therapy. If lesions do not indicate malignant change, however, they may be removed for cosmetic reasons, but aggressive surgery, such as Mohs micrographic surgery, may put the patient at risk for unnecessary infection and increased morbidity.1
Basaloid follicular hamartoma (BFH) is a benign adnexal tumor consisting of basaloid cells with follicular differentiation. BFH can occur as a solitary lesion, multiple lesions, or an autosomal dominant inherited syndrome—BFH syndrome (BFHS).1 In patients with BFHS, adnexal tumors predominantly occur on the head, neck, and torso. The syndrome often has coexisting hypotrichosis, hypohidrosis, and palmar/plantar pitting.1 A familial presentation of BFHS with palmar pitting is discussed with a review of BFHS, including the differential diagnosis of palmar pitting.
Case Report
A 67-year-old white woman presented to dermatology with a 20-year history of several lesions on her face that started as flesh-colored papules and progressively darkened. Most lesions were 3 to 6 mm and located symmetrically around the nose, mouth, chin, and eyes. The woman presented with her 39-year-old daughter, who had a 2-year history of similar lesions around her eyes, none in a perioral distribution. The women reported that when the mother's lesions first appeared, they had the same appearance as the daughter's lesions. The persistent lesions were otherwise asymptomatic. Review of systems for both the mother and daughter were negative for other cutaneous lesions and for systemic symptoms such as fever; weight loss; and cardiovascular, respiratory, gastrointestinal, and genitourinary symptoms. The mother's medical history was significant for hypertension, diabetes mellitus, hypothyroidism, and hypercholesterolemia. The daughter's medical history was significant only for diabetes mellitus. Results of a physical examination of the mother revealed hundreds of soft flesh-colored to hyperpigmented papules, most less than 6 mm in diameter. The papules coalesced in the perioral distribution (Figure 1). Results of a physical examination of the daughter revealed similar symmetric distribution of small (most 1–2 mm but all <6 mm in diameter) flesh-colored papules in bilateral nasolabial and periorbital areas. Symmetric palmar pitting was present in both women (Figure 2). The patients had no other clinical manifestations such as frontoparietal bossing, high arched palates, jaw cysts, short fourth metacarpals, ocular hypertelorism, or narrow sloping shoulders to suggest nevoid basal cell carcinoma syndrome (NBCS). Histopathology results of both the mother and daughter revealed adnexal proliferation with follicular differentiation consistent with BFH (Figures 3–5).
Comment
BFH is a rare benign adnexal tumor that exhibits protean clinical manifestations. Despite the polymorphic clinical presentations, lesions exhibit similar histologic appearance, with only small variations.1,2 Lesions exist in both solitary and multiple forms.1-4 Multiple forms generally exhibit autosomal dominant inheritance, while solitary forms usually are not inherited.3 The solitary noninherited forms are more common than the multiple autosomal dominant inherited forms.3,5
Most reported solitary cases of BFH are in women, aged 20 to 88 years (median, 66 years; mean, 63 years).3 Patients with multiple familial disease may exhibit associated systemic diseases, though systemic disease is less likely in patients with solitary lesions.2,3 Systemic diseases that may be associated with BFHS include hypertension, cardiovascular disease, renal disease, obesity, carpal tunnel syndrome, and cancer of the breast and stomach.6 Generalized lesions also have been associated with cystic fibrosis,7 systemic lupus erythematosus,8 and myasthenia gravis.9
BFHS lesions have a predilection for the face and scalp but also have been reported on the neck, axillae, shoulders, and pubic regions.4 Wheeler et al6 examined 18 members in one family and found that dominantly-inherited generalized BFHS exhibits variability of disease. The patients exhibited lesions that ranged from hundreds of pigmented papules with associated hypotrichosis and palmar/ plantar pitting to minimal facial papules and a few milia involving only the face.6 Most papules are 1 to 2 mm.3 In mild forms, the lesions may go unnoticed or may be mistaken as normal.6 Lesions also may be present at birth or may develop in early childhood.6,10-12
Findings on physical examination most commonly associated with BFHS include milialike papules, comedonal-like papules, hypotrichosis, hypohidrosis, and palmar/plantar pitting (Table).6 Less common associated findings include atopic dermatitis, keratosis pilaris, lichen striatus, acrochordons, acanthosis nigricans—like changes, dermatosis papulosa nigra, acne vulgaris, café au lait spots, punctate palmar keratosis, and steatocystoma multiplex.6
The differential diagnoses of multiple facial papules include angiofibromas (tuberous sclerosis), multiple trichilemmomas (Cowden disease), multiple trichoepitheliomas, multiple syringomas, steatocystoma multiplex, seborrheic keratosis, melanocytic nevi, sebaceous hyperplasia, and NBCS or Gorlin syndrome.3 NBCS is believed to be caused by a lack of human homoloque patched (PTCH) tumor suppressor gene function, whereas BFHS is reported to be caused by a decrease in PTCH function.13 Girardi et al10 suggested that familial BFHS possibly is a forme fruste of NBCS (ie, since both entities involve the PTCH gene protein product or some member of its pathway).
Histologically, branching cords and thin strands of undifferentiated and anastomosing basaloid proliferations, which are surrounded by a loosely fibroblastic stroma, identify BFH.1 This histologic pattern may be found in a wide spectrum of clinically nevoid presentations, and individual lesions may be indistinguishable from infundibulocystic basal cell carcinoma (BCC). Occasional peripheral pallisading, papillary mesenchymal bodies, and connections to the epidermis also have been described.1
BFH is categorized within the spectrum of basaloid epithelial neoplasms associated with dysregulation of the PTCH signaling pathway.13 However, in general, BFH lesions show less mitotic figures and necrosis when compared with BCC.6,13 Immunohistochemistry results show CD34+ stromal cells in peritumoral distribution, resembling trichoepithelioma and distinguishing the condition from BCC, which lacks CD34 expression.14 Additional factors that distinguish BFH from BCC include BFH’s low proliferative index (ie, low Ki-67) and lack of bcl-2 expression.13,14
BFHS is a rare entity. It is a mainly histologic diagnosis with varied clinical presentations.6 Prognosis is good and treatment usually is cosmetic with shave, curette, or scissor methods most frequently reported.3 Because of the benign nature of this follicular tumor, observation without treatment is an option. It is important to be able to recognize this disease to avoid overaggressive surgical management and to closely monitor for any new tumors that may develop in these lesions.1 Monitoring and close follow-up of these lesions is necessary because some believe that familial BFHS is possibly a forme fruste of NBCS. Any indications of malignant changes in these lesions (eg, nonhealing and bleeding lesions, biopsy suggestive of BCC or other skin cancer) warrant surgical therapy. If lesions do not indicate malignant change, however, they may be removed for cosmetic reasons, but aggressive surgery, such as Mohs micrographic surgery, may put the patient at risk for unnecessary infection and increased morbidity.1
- Nelson BR, Johnson TM, Waldinger T, et al. Basaloid follicular hamartoma: a histologic diagnosis with diverse clinical presentations. Arch Dermatol. 1993;129:915-917.
- Mehregan AH, Baker S. Basaloid follicular hamartoma: three cases with localized and systematized unilateral lesions. J Cutan Pathol. 1985;12:55-65.
- Brownstein MH. Basaloid follicular hamartoma: solitary and multiple types. J Am Acad Dermatol. 1992;27: 237-240.
- Walsh N, Ackerman AB. Basaloid follicular hamartoma. J Am Acad Dermatol. 1993;29:125-127.
- Ricks M, Elston DM, Sartori CR. Multiple basaloid follicular hamartomas associated with acrochordons, seborrheic keratoses, and chondrosarcoma. Br J Dermatol. 2002;146:1068-1070.
- Wheeler CE, Carroll MA, Groben PA, et al. Autosomal dominantly inherited generalized basaloid follicular hamartoma syndrome: report of a new disease in a North Carolina family. J Am Acad Dermatol. 2000;43:189-206.
- Mascaro JM, Ferrando J, Bombi JA, et al. Congenital generalized follicular hamartoma associated with alopecia and cystic fibrosis in three siblings. Arch Dermatol. 1995;131:454-458.
- Morton S, Stevens A, Powell RJ. Basaloid follicular hamartoma, total body hair loss and SLE. Lupus. 1998;7:207-209.
- Weltfriend S, David M, Ginzburg A, et al. Generalized hair follicle hamartoma: the third case report in association with myasthenia gravis. Am J Dermatopathol. 1987;9:428-432.
- Girardi M, Federman GL, McNiff JM. Familial multiple basaloid follicular hamartomas: a report of two affected sisters. Pediatr Dermatol. 1999;16:281-284.
- Metry D, Guill C. Generalized basaloid follicular hamartoma syndrome. J Am Acad Dermatol. 2001;45:644-645.
- Keough GC, Pierson JC, McCollough ML. A congenital pink plaque. Arch Dermatol. 1997;133:381-382, 384-385.
- Jih DM, Shapiro M, James WD, et al. Familial basaloid follicular hamartoma: lesional characterization and review of the literature. Am J Dermatopathol. 2003;25:130-137.
- Naeyaert JM, Pauwels C, Geerts ML, et al. CD-34 and Ki-67 staining patterns of basaloid follicular hamartoma are different from those in fibroepithelioma of Pinkus and other variants of basal cell carcinoma. J Cutan Pathol. 2001;28:538-541.
- Nelson BR, Johnson TM, Waldinger T, et al. Basaloid follicular hamartoma: a histologic diagnosis with diverse clinical presentations. Arch Dermatol. 1993;129:915-917.
- Mehregan AH, Baker S. Basaloid follicular hamartoma: three cases with localized and systematized unilateral lesions. J Cutan Pathol. 1985;12:55-65.
- Brownstein MH. Basaloid follicular hamartoma: solitary and multiple types. J Am Acad Dermatol. 1992;27: 237-240.
- Walsh N, Ackerman AB. Basaloid follicular hamartoma. J Am Acad Dermatol. 1993;29:125-127.
- Ricks M, Elston DM, Sartori CR. Multiple basaloid follicular hamartomas associated with acrochordons, seborrheic keratoses, and chondrosarcoma. Br J Dermatol. 2002;146:1068-1070.
- Wheeler CE, Carroll MA, Groben PA, et al. Autosomal dominantly inherited generalized basaloid follicular hamartoma syndrome: report of a new disease in a North Carolina family. J Am Acad Dermatol. 2000;43:189-206.
- Mascaro JM, Ferrando J, Bombi JA, et al. Congenital generalized follicular hamartoma associated with alopecia and cystic fibrosis in three siblings. Arch Dermatol. 1995;131:454-458.
- Morton S, Stevens A, Powell RJ. Basaloid follicular hamartoma, total body hair loss and SLE. Lupus. 1998;7:207-209.
- Weltfriend S, David M, Ginzburg A, et al. Generalized hair follicle hamartoma: the third case report in association with myasthenia gravis. Am J Dermatopathol. 1987;9:428-432.
- Girardi M, Federman GL, McNiff JM. Familial multiple basaloid follicular hamartomas: a report of two affected sisters. Pediatr Dermatol. 1999;16:281-284.
- Metry D, Guill C. Generalized basaloid follicular hamartoma syndrome. J Am Acad Dermatol. 2001;45:644-645.
- Keough GC, Pierson JC, McCollough ML. A congenital pink plaque. Arch Dermatol. 1997;133:381-382, 384-385.
- Jih DM, Shapiro M, James WD, et al. Familial basaloid follicular hamartoma: lesional characterization and review of the literature. Am J Dermatopathol. 2003;25:130-137.
- Naeyaert JM, Pauwels C, Geerts ML, et al. CD-34 and Ki-67 staining patterns of basaloid follicular hamartoma are different from those in fibroepithelioma of Pinkus and other variants of basal cell carcinoma. J Cutan Pathol. 2001;28:538-541.
Malignant Acanthosis Nigricans and Tripe Palms Associated With Pancreatic Adenocarcinoma
What Is Your Diagnosis? Cowden Disease (Multiple Hamartoma Syndrome)
Bednar Tumor: Treatment With Mohs Micrographic Surgery
Superior Vena Cava Syndrome: A Case Report
Primary Cutaneous Adenoid Cystic Carcinoma: A Case Report and Literature Review
Adenoid cystic carcinoma (ACC) is a well-known tumor of the salivary glands and oral cavity that accounts for 10% to 15% of all head and neck tumors worldwide.1 In contrast, primary cutaneous ACC is a rare tumor, with less than 50 cases reported to date.2-10 We report an additional case of primary cutaneous ACC and describe the clinical presentation, histologic findings, and subsequent treatment. A brief review of the literature also is provided.
Case Report
A 57-year-old white woman presented to her dermatologist with a one-year history of an enlarging flesh-colored nodule on the left side of the scalp. The patient's medical history was significant only for bradycardia and hypertension. The results of a biopsy of a tumor specimen revealed a large neoplasm composed of epithelial cells that filled the entire dermis (Figure). There was no connection between the tumor and the epidermis. The tumor cells were arranged in multiple lobules that varied in size and shape and that were separated by fibrous stroma. Some of the lobules showed cystic change and others showed ductal differentiation, imparting an overall cribriform appearance to the tumor. The tumor cells were small and basophilic in nature. Perineural invasion was not present. The findings were characteristic of ACC.
The patient underwent Mohs micrographic surgery for excision of the tumor. Clearance was achieved in 3 stages. The final defect measured 3.0x3.5 cm, extended through the periosteum, and primarily was closed. To rule out an extracutaneous primary site, computed tomography scans were obtained of the head, neck, chest, and abdomen. The scan results were unremarkable. The patient had no symptomatology of her head or neck. Results of an examination by an otolaryngologist revealed no abnormalities of the minor salivary glands, parotid glands, submandibular glands, tongue, oropharyngeal and nasal cavities, or ears. The patient then underwent 33 local radiation treatments to the scalp (total radiation dose of 5940 cGy) to decrease the possibility of recurrence. At 28 months postsurgery, she had no signs of recurrence.
Comment
ACC accounts for about 10% to 15% of head and neck tumors and most frequently occurs in the major and minor salivary glands; other sites that may be involved include the tracheobronchial tree, esophagus, lacrimal gland, ear canal, breast, uterine cervix, Bartholin glands, prostate, mucosal glands of the upper respiratory tract, and skin.1,4,11 ACC of the head and neck usually is a slow-growing tumor. Local recurrences are frequent; and metastasis, which occurs in 21% to 54% of cases, tends to involve the lung, liver, bone, and brain.12-14 Cutaneous metastasis from ACC of the head and neck is rare.15,16 Primary cutaneous ACC is a rare tumor that was first reported by Boggio in 1975.2 Primary cutaneous ACC most commonly involves the scalp and presents as a slow-growing nondescript nodule. The local recurrence rate after excision is approximately 50%.3,17 Nodal metastasis from primary cutaneous ACC is rare.3,4 To our knowledge, 5 cases of visceral metastasis from primary cutaneous ACC have been reported.7,8 Histologically, the tumor is composed of epithelial cells arranged into multiple lobules, many of which show cystic change and therefore impart a cribriform appearance to the tumor. There is no connection between the tumor lobules and the epidermis. The tumor displays an infiltrating pattern that fills the entire dermis and that frequently invades the subcutaneous tissue. Perineural invasion is seen in approximately one half of cases; vascular invasion occurs less commonly.8,18,19 Basophilic mucinous material is present within the cystic lobules, and the stroma between the lobules is fibrous. The epithelial cells are small and basophilic with scant cytoplasm. Mitotic figures are rare. In addition to the cribriform areas, tubular foci sometimes are found.15,18 The main tumor that histologically may mimic primary cutaneous ACC is adenoid basal cell carcinoma. Both tumors are composed of small epithelial cells with minimal cytoplasm that are arranged into multiple cystic lobules, giving rise to an adenoid or cribriform appearance; additionally, both tumors contain abundant mucin. Adenoid basal cell carcinoma differs from primary cutaneous ACC in several ways: the tumor lobules may connect with the epidermis; perineural invasion is rare; peripheral palisading and retraction artifact may be present; and the stroma may be more cellular.5,19 Immunohistochemical staining may be useful in distinguishing tumors that are difficult to differentiate based on the results of histologic evaluations (Table).17,19
The cell of origin for primary cutaneous ACC is not known. Many authors believe that primary cutaneous ACC arises from the eccrine gland or duct; however, primary cutaneous ACC also occurs in the ear canal, which does not contain eccrine glands. Furthermore, ACC can arise in a variety of different organs. Therefore, ACC likely has a different cell of origin in different locations in the body, all of which give rise to tumors with a similar histologic appearance.5,8 Treatment recommendations for primary cutaneous ACC consist of either wide local excision or Mohs micrographic surgery.7-9,17,18 The high rate of perineural spread accounts for the large recurrence rate after local excision with minimal margins or without micrographic control. One group has used Mohs micrographic surgery using a toluidine blue stain (instead of the usual hematoxylin-eosin stain), which metachromatically stains the abundant mucin found within the tumor and may help to better delineate the tumor's margins.10 Some patients have had adjuvant local radiation therapy to decrease recurrence rates,7 but some clinicians find radiation to be ineffective.18,19 Visceral metastases from primary cutaneous ACC either have been treated with chemotherapy or have been monitored radiographically.7,8 In summary, primary cutaneous ACC is a rare tumor and is much less common than ACC arising in other sites. Therefore, a diagnosis of primary cutaneous ACC should be considered only after an extracutaneous origin has been ruled out. Because ACC most frequently arises from the salivary glands (and less commonly from other locations in the head and neck or elsewhere in the body), a complete physical examination of the head and neck region, preferably by an otolaryngologist, should be performed. Additional imaging studies may be useful. Because the risk of local recurrence is high, the authors recommend Mohs micrographic surgery for treatment of this tumor. Additionally, adjuvant radiation treatment may be helpful.
- Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96:149-158.
- Boggio R. Adenoid cystic carcinoma of the scalp. Arch Dermatol. 1975;111:793-794.
- Weekly M, Lydiatt DD, Lydiatt WM, et al. Primary cutaneous adenoid cystic carcinoma metastatic to cervical lymph nodes. Head Neck. 2000;22:84-86.
- Chu SS, Chang YL, Lou PJ. Primary cutaneous adenoid cystic carcinoma with regional lymph node metastasis. J Laryngol Otol. 2001;115:673-675.
- Seab JA, Graham JH. Primary cutaneous adenoid cystic carcinoma. J Am Acad Dermatol. 1987;17:113-118.
- Marback EF, Costa AL, Nossa LMB, et al. Eyelid skin adenoid cystic carcinoma: a clinicopathological study of one case simulating sebaceous gland carcinoma. Br J Opthalmol. 2003;87:118-125.
- Pappo O, Gez E, Craciun I, et al. Growth rate analysis of lung metastases appearing 18 years after resection of cutaneous adenoid cystic carcinoma. case report and review of the literature. Arch Pathol Lab Med. 1992;116:76-79.
- Chang SE, Ahn SJ, Choi JH, et al. Primary adenoid cystic carcinoma of skin with lung metastasis. J Am Acad Dermatol. 1999;40:640-642.
- Irvine AD, Kenny B, Walsh MY, et al. Primary cutaneous adenoid cystic carcinoma. Clin Exp Dermatol. 1996;21:249-250.
- Chesser RS, Bertler DE, Fitzpatrick JE, et al. Primary cutaneous adenoid cystic carcinoma treated with Mohs micrographic surgery toluidine blue technique. J Dermatol Surg Oncol. 1992;18:175-176.
- Perzin KH, Gullane P, Conley J. Adenoid cystic carcinoma involving the external auditory canal: a clinicopathologic study of 16 cases. Cancer. 1982;50:2873-2883.
- Fordice J, Kershaw C, El-Naggar A, et al. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999;125:149-152.
- van der Wal JE, Becking AG, Snow GB, et al. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck. 2002;24:779-783.
- Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary gland origin. Am J Surg. 1997;174:495-498.
- Chang CH, Liao YL, Hong HS. Cutaneous metastasis from adenoid cystic carcinoma of the parotid gland. Dermatol Surg. 2003;29:775-779.
- Nakamura M, Miyachi Y. Cutaneous metastasis from an adenoid cystic carcinoma of the lacrimal gland. Br J Dermatol. 1999;141:373-374.
- van der Kwast TH, Vuzevski VD, Ramaekers F, et al. Primary cutaneous adenoid cystic carcinoma: case report, immunohistochemistry, and review of the literature. Br J Dermatol. 1988;118:567-577.
- Cooper PH, Adelson GL, Holthaus WH. Primary cutaneous adenoid cystic carcinoma. Arch Dermatol. 1984;120:774-777.
- Wick MR, Swanson, PE. Primary adenoid cystic carcinoma of the skin. a clinical, histological, and immunocytochemical comparison with adenoid cystic carcinoma of salivary glands and adenoid basal cell carcinoma. Am J Derma
Adenoid cystic carcinoma (ACC) is a well-known tumor of the salivary glands and oral cavity that accounts for 10% to 15% of all head and neck tumors worldwide.1 In contrast, primary cutaneous ACC is a rare tumor, with less than 50 cases reported to date.2-10 We report an additional case of primary cutaneous ACC and describe the clinical presentation, histologic findings, and subsequent treatment. A brief review of the literature also is provided.
Case Report
A 57-year-old white woman presented to her dermatologist with a one-year history of an enlarging flesh-colored nodule on the left side of the scalp. The patient's medical history was significant only for bradycardia and hypertension. The results of a biopsy of a tumor specimen revealed a large neoplasm composed of epithelial cells that filled the entire dermis (Figure). There was no connection between the tumor and the epidermis. The tumor cells were arranged in multiple lobules that varied in size and shape and that were separated by fibrous stroma. Some of the lobules showed cystic change and others showed ductal differentiation, imparting an overall cribriform appearance to the tumor. The tumor cells were small and basophilic in nature. Perineural invasion was not present. The findings were characteristic of ACC.
The patient underwent Mohs micrographic surgery for excision of the tumor. Clearance was achieved in 3 stages. The final defect measured 3.0x3.5 cm, extended through the periosteum, and primarily was closed. To rule out an extracutaneous primary site, computed tomography scans were obtained of the head, neck, chest, and abdomen. The scan results were unremarkable. The patient had no symptomatology of her head or neck. Results of an examination by an otolaryngologist revealed no abnormalities of the minor salivary glands, parotid glands, submandibular glands, tongue, oropharyngeal and nasal cavities, or ears. The patient then underwent 33 local radiation treatments to the scalp (total radiation dose of 5940 cGy) to decrease the possibility of recurrence. At 28 months postsurgery, she had no signs of recurrence.
Comment
ACC accounts for about 10% to 15% of head and neck tumors and most frequently occurs in the major and minor salivary glands; other sites that may be involved include the tracheobronchial tree, esophagus, lacrimal gland, ear canal, breast, uterine cervix, Bartholin glands, prostate, mucosal glands of the upper respiratory tract, and skin.1,4,11 ACC of the head and neck usually is a slow-growing tumor. Local recurrences are frequent; and metastasis, which occurs in 21% to 54% of cases, tends to involve the lung, liver, bone, and brain.12-14 Cutaneous metastasis from ACC of the head and neck is rare.15,16 Primary cutaneous ACC is a rare tumor that was first reported by Boggio in 1975.2 Primary cutaneous ACC most commonly involves the scalp and presents as a slow-growing nondescript nodule. The local recurrence rate after excision is approximately 50%.3,17 Nodal metastasis from primary cutaneous ACC is rare.3,4 To our knowledge, 5 cases of visceral metastasis from primary cutaneous ACC have been reported.7,8 Histologically, the tumor is composed of epithelial cells arranged into multiple lobules, many of which show cystic change and therefore impart a cribriform appearance to the tumor. There is no connection between the tumor lobules and the epidermis. The tumor displays an infiltrating pattern that fills the entire dermis and that frequently invades the subcutaneous tissue. Perineural invasion is seen in approximately one half of cases; vascular invasion occurs less commonly.8,18,19 Basophilic mucinous material is present within the cystic lobules, and the stroma between the lobules is fibrous. The epithelial cells are small and basophilic with scant cytoplasm. Mitotic figures are rare. In addition to the cribriform areas, tubular foci sometimes are found.15,18 The main tumor that histologically may mimic primary cutaneous ACC is adenoid basal cell carcinoma. Both tumors are composed of small epithelial cells with minimal cytoplasm that are arranged into multiple cystic lobules, giving rise to an adenoid or cribriform appearance; additionally, both tumors contain abundant mucin. Adenoid basal cell carcinoma differs from primary cutaneous ACC in several ways: the tumor lobules may connect with the epidermis; perineural invasion is rare; peripheral palisading and retraction artifact may be present; and the stroma may be more cellular.5,19 Immunohistochemical staining may be useful in distinguishing tumors that are difficult to differentiate based on the results of histologic evaluations (Table).17,19
The cell of origin for primary cutaneous ACC is not known. Many authors believe that primary cutaneous ACC arises from the eccrine gland or duct; however, primary cutaneous ACC also occurs in the ear canal, which does not contain eccrine glands. Furthermore, ACC can arise in a variety of different organs. Therefore, ACC likely has a different cell of origin in different locations in the body, all of which give rise to tumors with a similar histologic appearance.5,8 Treatment recommendations for primary cutaneous ACC consist of either wide local excision or Mohs micrographic surgery.7-9,17,18 The high rate of perineural spread accounts for the large recurrence rate after local excision with minimal margins or without micrographic control. One group has used Mohs micrographic surgery using a toluidine blue stain (instead of the usual hematoxylin-eosin stain), which metachromatically stains the abundant mucin found within the tumor and may help to better delineate the tumor's margins.10 Some patients have had adjuvant local radiation therapy to decrease recurrence rates,7 but some clinicians find radiation to be ineffective.18,19 Visceral metastases from primary cutaneous ACC either have been treated with chemotherapy or have been monitored radiographically.7,8 In summary, primary cutaneous ACC is a rare tumor and is much less common than ACC arising in other sites. Therefore, a diagnosis of primary cutaneous ACC should be considered only after an extracutaneous origin has been ruled out. Because ACC most frequently arises from the salivary glands (and less commonly from other locations in the head and neck or elsewhere in the body), a complete physical examination of the head and neck region, preferably by an otolaryngologist, should be performed. Additional imaging studies may be useful. Because the risk of local recurrence is high, the authors recommend Mohs micrographic surgery for treatment of this tumor. Additionally, adjuvant radiation treatment may be helpful.
Adenoid cystic carcinoma (ACC) is a well-known tumor of the salivary glands and oral cavity that accounts for 10% to 15% of all head and neck tumors worldwide.1 In contrast, primary cutaneous ACC is a rare tumor, with less than 50 cases reported to date.2-10 We report an additional case of primary cutaneous ACC and describe the clinical presentation, histologic findings, and subsequent treatment. A brief review of the literature also is provided.
Case Report
A 57-year-old white woman presented to her dermatologist with a one-year history of an enlarging flesh-colored nodule on the left side of the scalp. The patient's medical history was significant only for bradycardia and hypertension. The results of a biopsy of a tumor specimen revealed a large neoplasm composed of epithelial cells that filled the entire dermis (Figure). There was no connection between the tumor and the epidermis. The tumor cells were arranged in multiple lobules that varied in size and shape and that were separated by fibrous stroma. Some of the lobules showed cystic change and others showed ductal differentiation, imparting an overall cribriform appearance to the tumor. The tumor cells were small and basophilic in nature. Perineural invasion was not present. The findings were characteristic of ACC.
The patient underwent Mohs micrographic surgery for excision of the tumor. Clearance was achieved in 3 stages. The final defect measured 3.0x3.5 cm, extended through the periosteum, and primarily was closed. To rule out an extracutaneous primary site, computed tomography scans were obtained of the head, neck, chest, and abdomen. The scan results were unremarkable. The patient had no symptomatology of her head or neck. Results of an examination by an otolaryngologist revealed no abnormalities of the minor salivary glands, parotid glands, submandibular glands, tongue, oropharyngeal and nasal cavities, or ears. The patient then underwent 33 local radiation treatments to the scalp (total radiation dose of 5940 cGy) to decrease the possibility of recurrence. At 28 months postsurgery, she had no signs of recurrence.
Comment
ACC accounts for about 10% to 15% of head and neck tumors and most frequently occurs in the major and minor salivary glands; other sites that may be involved include the tracheobronchial tree, esophagus, lacrimal gland, ear canal, breast, uterine cervix, Bartholin glands, prostate, mucosal glands of the upper respiratory tract, and skin.1,4,11 ACC of the head and neck usually is a slow-growing tumor. Local recurrences are frequent; and metastasis, which occurs in 21% to 54% of cases, tends to involve the lung, liver, bone, and brain.12-14 Cutaneous metastasis from ACC of the head and neck is rare.15,16 Primary cutaneous ACC is a rare tumor that was first reported by Boggio in 1975.2 Primary cutaneous ACC most commonly involves the scalp and presents as a slow-growing nondescript nodule. The local recurrence rate after excision is approximately 50%.3,17 Nodal metastasis from primary cutaneous ACC is rare.3,4 To our knowledge, 5 cases of visceral metastasis from primary cutaneous ACC have been reported.7,8 Histologically, the tumor is composed of epithelial cells arranged into multiple lobules, many of which show cystic change and therefore impart a cribriform appearance to the tumor. There is no connection between the tumor lobules and the epidermis. The tumor displays an infiltrating pattern that fills the entire dermis and that frequently invades the subcutaneous tissue. Perineural invasion is seen in approximately one half of cases; vascular invasion occurs less commonly.8,18,19 Basophilic mucinous material is present within the cystic lobules, and the stroma between the lobules is fibrous. The epithelial cells are small and basophilic with scant cytoplasm. Mitotic figures are rare. In addition to the cribriform areas, tubular foci sometimes are found.15,18 The main tumor that histologically may mimic primary cutaneous ACC is adenoid basal cell carcinoma. Both tumors are composed of small epithelial cells with minimal cytoplasm that are arranged into multiple cystic lobules, giving rise to an adenoid or cribriform appearance; additionally, both tumors contain abundant mucin. Adenoid basal cell carcinoma differs from primary cutaneous ACC in several ways: the tumor lobules may connect with the epidermis; perineural invasion is rare; peripheral palisading and retraction artifact may be present; and the stroma may be more cellular.5,19 Immunohistochemical staining may be useful in distinguishing tumors that are difficult to differentiate based on the results of histologic evaluations (Table).17,19
The cell of origin for primary cutaneous ACC is not known. Many authors believe that primary cutaneous ACC arises from the eccrine gland or duct; however, primary cutaneous ACC also occurs in the ear canal, which does not contain eccrine glands. Furthermore, ACC can arise in a variety of different organs. Therefore, ACC likely has a different cell of origin in different locations in the body, all of which give rise to tumors with a similar histologic appearance.5,8 Treatment recommendations for primary cutaneous ACC consist of either wide local excision or Mohs micrographic surgery.7-9,17,18 The high rate of perineural spread accounts for the large recurrence rate after local excision with minimal margins or without micrographic control. One group has used Mohs micrographic surgery using a toluidine blue stain (instead of the usual hematoxylin-eosin stain), which metachromatically stains the abundant mucin found within the tumor and may help to better delineate the tumor's margins.10 Some patients have had adjuvant local radiation therapy to decrease recurrence rates,7 but some clinicians find radiation to be ineffective.18,19 Visceral metastases from primary cutaneous ACC either have been treated with chemotherapy or have been monitored radiographically.7,8 In summary, primary cutaneous ACC is a rare tumor and is much less common than ACC arising in other sites. Therefore, a diagnosis of primary cutaneous ACC should be considered only after an extracutaneous origin has been ruled out. Because ACC most frequently arises from the salivary glands (and less commonly from other locations in the head and neck or elsewhere in the body), a complete physical examination of the head and neck region, preferably by an otolaryngologist, should be performed. Additional imaging studies may be useful. Because the risk of local recurrence is high, the authors recommend Mohs micrographic surgery for treatment of this tumor. Additionally, adjuvant radiation treatment may be helpful.
- Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96:149-158.
- Boggio R. Adenoid cystic carcinoma of the scalp. Arch Dermatol. 1975;111:793-794.
- Weekly M, Lydiatt DD, Lydiatt WM, et al. Primary cutaneous adenoid cystic carcinoma metastatic to cervical lymph nodes. Head Neck. 2000;22:84-86.
- Chu SS, Chang YL, Lou PJ. Primary cutaneous adenoid cystic carcinoma with regional lymph node metastasis. J Laryngol Otol. 2001;115:673-675.
- Seab JA, Graham JH. Primary cutaneous adenoid cystic carcinoma. J Am Acad Dermatol. 1987;17:113-118.
- Marback EF, Costa AL, Nossa LMB, et al. Eyelid skin adenoid cystic carcinoma: a clinicopathological study of one case simulating sebaceous gland carcinoma. Br J Opthalmol. 2003;87:118-125.
- Pappo O, Gez E, Craciun I, et al. Growth rate analysis of lung metastases appearing 18 years after resection of cutaneous adenoid cystic carcinoma. case report and review of the literature. Arch Pathol Lab Med. 1992;116:76-79.
- Chang SE, Ahn SJ, Choi JH, et al. Primary adenoid cystic carcinoma of skin with lung metastasis. J Am Acad Dermatol. 1999;40:640-642.
- Irvine AD, Kenny B, Walsh MY, et al. Primary cutaneous adenoid cystic carcinoma. Clin Exp Dermatol. 1996;21:249-250.
- Chesser RS, Bertler DE, Fitzpatrick JE, et al. Primary cutaneous adenoid cystic carcinoma treated with Mohs micrographic surgery toluidine blue technique. J Dermatol Surg Oncol. 1992;18:175-176.
- Perzin KH, Gullane P, Conley J. Adenoid cystic carcinoma involving the external auditory canal: a clinicopathologic study of 16 cases. Cancer. 1982;50:2873-2883.
- Fordice J, Kershaw C, El-Naggar A, et al. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999;125:149-152.
- van der Wal JE, Becking AG, Snow GB, et al. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck. 2002;24:779-783.
- Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary gland origin. Am J Surg. 1997;174:495-498.
- Chang CH, Liao YL, Hong HS. Cutaneous metastasis from adenoid cystic carcinoma of the parotid gland. Dermatol Surg. 2003;29:775-779.
- Nakamura M, Miyachi Y. Cutaneous metastasis from an adenoid cystic carcinoma of the lacrimal gland. Br J Dermatol. 1999;141:373-374.
- van der Kwast TH, Vuzevski VD, Ramaekers F, et al. Primary cutaneous adenoid cystic carcinoma: case report, immunohistochemistry, and review of the literature. Br J Dermatol. 1988;118:567-577.
- Cooper PH, Adelson GL, Holthaus WH. Primary cutaneous adenoid cystic carcinoma. Arch Dermatol. 1984;120:774-777.
- Wick MR, Swanson, PE. Primary adenoid cystic carcinoma of the skin. a clinical, histological, and immunocytochemical comparison with adenoid cystic carcinoma of salivary glands and adenoid basal cell carcinoma. Am J Derma
- Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96:149-158.
- Boggio R. Adenoid cystic carcinoma of the scalp. Arch Dermatol. 1975;111:793-794.
- Weekly M, Lydiatt DD, Lydiatt WM, et al. Primary cutaneous adenoid cystic carcinoma metastatic to cervical lymph nodes. Head Neck. 2000;22:84-86.
- Chu SS, Chang YL, Lou PJ. Primary cutaneous adenoid cystic carcinoma with regional lymph node metastasis. J Laryngol Otol. 2001;115:673-675.
- Seab JA, Graham JH. Primary cutaneous adenoid cystic carcinoma. J Am Acad Dermatol. 1987;17:113-118.
- Marback EF, Costa AL, Nossa LMB, et al. Eyelid skin adenoid cystic carcinoma: a clinicopathological study of one case simulating sebaceous gland carcinoma. Br J Opthalmol. 2003;87:118-125.
- Pappo O, Gez E, Craciun I, et al. Growth rate analysis of lung metastases appearing 18 years after resection of cutaneous adenoid cystic carcinoma. case report and review of the literature. Arch Pathol Lab Med. 1992;116:76-79.
- Chang SE, Ahn SJ, Choi JH, et al. Primary adenoid cystic carcinoma of skin with lung metastasis. J Am Acad Dermatol. 1999;40:640-642.
- Irvine AD, Kenny B, Walsh MY, et al. Primary cutaneous adenoid cystic carcinoma. Clin Exp Dermatol. 1996;21:249-250.
- Chesser RS, Bertler DE, Fitzpatrick JE, et al. Primary cutaneous adenoid cystic carcinoma treated with Mohs micrographic surgery toluidine blue technique. J Dermatol Surg Oncol. 1992;18:175-176.
- Perzin KH, Gullane P, Conley J. Adenoid cystic carcinoma involving the external auditory canal: a clinicopathologic study of 16 cases. Cancer. 1982;50:2873-2883.
- Fordice J, Kershaw C, El-Naggar A, et al. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999;125:149-152.
- van der Wal JE, Becking AG, Snow GB, et al. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck. 2002;24:779-783.
- Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary gland origin. Am J Surg. 1997;174:495-498.
- Chang CH, Liao YL, Hong HS. Cutaneous metastasis from adenoid cystic carcinoma of the parotid gland. Dermatol Surg. 2003;29:775-779.
- Nakamura M, Miyachi Y. Cutaneous metastasis from an adenoid cystic carcinoma of the lacrimal gland. Br J Dermatol. 1999;141:373-374.
- van der Kwast TH, Vuzevski VD, Ramaekers F, et al. Primary cutaneous adenoid cystic carcinoma: case report, immunohistochemistry, and review of the literature. Br J Dermatol. 1988;118:567-577.
- Cooper PH, Adelson GL, Holthaus WH. Primary cutaneous adenoid cystic carcinoma. Arch Dermatol. 1984;120:774-777.
- Wick MR, Swanson, PE. Primary adenoid cystic carcinoma of the skin. a clinical, histological, and immunocytochemical comparison with adenoid cystic carcinoma of salivary glands and adenoid basal cell carcinoma. Am J Derma
Syringomatous Carcinoma in a Young Patient Treated With Mohs Micrographic Surgery
Syringomatous carcinoma (SC), considered by some to be a variant of microcystic adnexal carcinoma (MAC),1 is a rare malignant neoplasm of sweat gland origin. SC encompasses a range of neoplasms with different degrees of differentiation, and its nomenclature has varied over the years. SC also has been referred to as syringoid eccrine carcinoma,2 basal cell tumor with eccrine differentiation,3 malignant syringoma,4 and sclerosing sweat duct carcinoma.5 Its diagnosis has been a dilemma in a number of reported cases, probably due to the combination of its rarity and thus limited clinical and histopathologic information, microscopic similarities to other benign and malignant neoplasms, and characteristic histologic features that may only be apparent in surgical excisions containing deeper tissue. We report a case of SC that masqueraded as an epidermoid cyst in an unusually young patient.
Case Report
A 23-year-old Asian man, who was otherwise healthy, presented with an asymptomatic slowly enlarging nodule of one year's duration on the right medial eyebrow. Prior treatment with intralesional steroid injections resulted in minimal improvement. The patient had no personal or family history of skin cancers. Physical examination results demonstrated a well-demarcated, mobile, nontender subcutaneous nodule measuring 7 mm in diameter. The clinical presentation favored a diagnosis of an epidermal inclusion cyst, and the patient underwent surgical excision of the lesion. Results of the histopathologic examination revealed a neoplasm in the dermis consisting of bands and nests of pale staining basaloid cells extending between the collagen fibers (Figure 1). There were focal areas of ductal differentiation, scattered individual necrotic cells, moderate dermal fibrosis, and chronic inflammation with numerous eo-sinophils. Moderate nuclear atypia also was present (Figure 2). Perineural involvement was not seen. Results of immunohistochemical analysis revealed positive staining for high—and low—molecular-weight cytokeratins, as well as carcinoembryonic antigen (CEA)(Figure 3). There was scattered positivity with S-100 protein in occasional cells lining lumina and in dendritic cells (Figure 4). The histopathologic findings supported the diagnosis of SC. Because the neoplasm extended to the surgical margins of the specimen, repeat surgical excision with continuous microscopic control under the Mohs micrographic technique was performed to prevent local recurrence and spare normal tissue. At the 18-month follow-up visit, no local recurrence was seen.
Comment SC is a rare, malignant sweat gland neoplasm that usually occurs in the fourth and fifth decades of life.4-8 SC typically presents as a slow-growing, solitary, painless nodule or indurated plaque on the head or neck region.6-8 It has been frequently found on the upper and lower lips; however, it also has been reported to occur on the finger and breast.9,10 Predisposing factors for the development of SC are unclear11 but may include previous radiation to the face and history of receiving an organ transplant with immunosuppressive drug therapy.12-17 Histopathologically, SC is characterized by asymmetric and deep dermal invasion of tumor cells, perineural involvement, ductal formation, keratin-filled cysts, multiple nests of basaloid or squamous cells, and desmoplasia of the surrounding dermal stroma (Table 1).5,6 Some authors consider SC to be closely related to MAC but generally describe SC as more basaloid with larger tubules and a more sclerotic stroma than MAC.18-26 If histologic examination of SC is limited to the superficial dermis, SC demonstrates similarities to other neoplasms, including syringomas, trichoadenomas, trichoepitheliomas, basal cell carcinomas, or squamous cell carcinomas. In the reported cases in which SC was initially misdiagnosed as another benign or malignant neoplasm, many misdiagnoses were due to either a benign clinical appearance of the lesion or biopsy specimens that were too superficial to contain the deeper characteristic histologic features of SC.8,9,11,27-30
Immunohistochemical studies can facilitate the diagnosis of SC and differentiate it from other neoplasms. SC stains positively for CEA, S-100 protein, epithelial membrane antigen, cyto-keratin, and gross cystic disease fluid protein 15,31 all of which aid in the confirmation of a sweat gland neoplasm (Table 2).8,32,33,39 Positivity for CEA in the ductal lining cells and the luminal contents of tumor ducts confirms sweat gland differentiation.25,33,34 This ductal immunoreactivity to CEA appears to be one of the most reliable findings to differentiate SC and MAC from other adnexal tumors, especially desmoplastic trichoepithelioma, which may be one of the more challenging histo-pathologic differential diagnoses.35 In addition, epithelial membrane antigen positivity can be found in the areas showing glandular features.35 This can assist in distinguishing SC from a desmoplastic trichoepithelioma or sclerosing type basal cell carcinoma, both of which demonstrate negativity to epithelial membrane antigen.35 S-100 protein positivity in dendritic cells, as well as in some cords and ducts in SC, further verifies dendritic differentiation toward sweat gland structures and is useful as an adjunct in the confirmation of glandular differentiation.25,33,34,36
Without proper and timely diagnosis and management, SC can cause severe patient morbidity. Although SC rarely metastasizes and can have an indolent course, it can be locally de-structive and lead to potentially disfiguring outcomes.5-7 SC can invade deeply and infiltrate into the dermis, subcutaneous fat tissue, muscle, perichondrium, periosteum, and galea.8 Goto et al9 reported a case of an SC that was initially misdiagnosed as a basal cell carcinoma of the left middle finger. The deeper, characteristic features of SC were not recognized until after the affected finger required amputation due to erosion of the bone. Hoppenreijs et al11 described an aggressive case of an SC arising at a site of previously irradiated squamous cell carcinoma of the lower eyelid. Extensive involvement of the SC in the orbit led to the recommendation of an orbital exenter-ation; however, it was not performed because of the poor clinical condition of the patient. Treatments for SC have included wide local excision and Mohs micrographic surgery (MMS). SC treatment with wide local excision often resulted in incomplete excision of the neoplasm despite having taken an adequate margin around the clinically assessable tumor.5 Cases of SC treated with wide local excision had a recurrence rate of 47%.5 The positive surgical margins following wide local excision may be due to the deep infiltration of SC, which frequently exceeds the clinically predicted size of the tumor.5 Due to the close relationship of MAC and SC, we feel that MMS treatment of SC will reduce recurrences as it has for MAC. Currently, there is strong support for the treatment of MAC with MMS as a gold standard to ensure complete clearance of the neoplasm and to reduce the local recurrence rate.12,13,17,21,22,37,38 In a study of MAC by Chiller et al,37 the authors demonstrated a median 4-fold increase in defect size when they compared the clinically estimated pretreatment size of the lesion with the MMS-determined posttreatment size of the lesion. The authors therefore suggest that, similar to the MMS-treated lesions, the lesions completely treated with wide local excision also would produce a defect size that is at least 4 times greater than the predicted pretreatment size of the lesion. Because wide local excision relies on predicted margins of the lesion, which the authors have shown can be greatly underestimated, Chiller et al37 argue that the use of MMS, which does not rely on predicted margins, is a reasonable first-line therapeutic modality for effectively treating patients with MAC. Furthermore, MMS allows for the examination of the entire peripheral and deep margins of the lesion, which is critical when considering the deep infiltrative nature of MAC. The reported local recurrence rate of MAC treated with MMS is 0% to 5%,12,13,21,26,38 which is much lower than the reported local recurrence rate following treatment with wide local excision. This reduced recurrence rate found in MAC cases treated with MMS is probably due to the ability to confirm complete removal of the neoplasm with MMS.
Conclusion To our knowledge, this case report describes the occurrence of SC, a rare sweat gland neoplasm, in the youngest reported patient and is only the second reported case of SC treated with MMS. Adequate sampling of tissue with an excisional biopsy allowed for appropriate evaluation with histologic and immunohistochemical studies to arrive at the diagnosis that could easily have been missed with a superficial biopsy. In our patient, histopathologic evaluation showed typical nests of basaloid cells, ductal differentiation, and ductal fibrosis seen in SC. However, perineural involvement that is particularly characteristic of SC was not present. This may portend a better prognosis for our patient whose tumor was completely excised after one stage of MMS and has not shown evidence of recurrence at the 18-month follow-up visit. MMS allowed for evaluation of the entire surgical margin and decreased risk of local recurrence resulting from an incomplete excision. In addition, it also allowed for sparing of normal tissue in a cosmetically sensitive area where SC commonly occurs. In summary, this case highlights the importance of including SC in the differential diagnosis of an enlarging cystic lesion in a younger patient and its successful treatment with MMS.
- Weedon D. Tumors of cutaneous appendages. In: Weedon D, ed. Skin Pathology. 2nd ed. London, England: Churchill Livingstone; 2002:897.
- Sanchez Yus E, Requena Caballero L, Garcia Salazar I, et al. Clear cell syringoid eccrine carcinoma. Am J Dermatopathol. 1987;9:225-231.
- Freeman RG, Winkelmann RK. Basal cell tumor with eccrine differentiation (eccrine epithelioma). Arch Dermatol. 1969;100:234-242.
- Glatt HJ, Proia AD, Tsoy EA, et al. Malignant syringoma of the eyelid. Ophthalmology. 1984;91:987-990.
- Cooper PH, Mills SE, Leonard DD, et al. Sclerosing sweat duct (syringomatous) carcinoma. Am J Surg Pathol. 1985;9:422-433.
- Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: a clinicopathologic study of 35 cases. Arch Dermatol. 1983;119:104-114.
- Wick MR, Goellner JR, Wolfe JT III, et al. Adnexal carcinomas of the skin, I: eccrine carcinomas. Cancer. 1985;56:1147-1162.
- Abenoza P, Ackerman AB. Syringomatous carcinomas. In: Abenoza P, Ackerman AB, eds. Neoplasms with Eccrine Differentiation. Philadelphia, Pa: Lea & Febiger; 1990:371-412.
- Goto M, Sonoda T, Shibuya H, et al. Digital syringomatous carcinoma mimicking basal cell carcinoma. Br J Dermatol. 2001;144:438-439.
- Urso C. Syringomatous breast carcinoma and correlated lesions. Pathologica. 1996;88:196-199.
- Hoppenreijs VP, Reuser TT, Mooy CM, et al. Syringomatous carcinoma of the eyelid and orbit: a clinical and histopathological challenge. Br J Ophthalmol. 1997;81:668-672.
- Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27:401-408.
- Friedman PM, Friedman RH, Jiang SB, et al. Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol. 1999;41:225-231.
- Antley CA, Carney M, Smoller BR. Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. J Cutan Pathol. 1999;26:48-50.
- Borenstein A, Seidman DS, Trau H, et al. Microcystic adnexal carcinoma following radiotherapy in childhood. Am J Med Sci. 1991;301:259-261.
- Fleischmann HE, Roth RJ, Wood C, et al. Microcystic adnexal carcinoma treated by microscopically controlled excision. J Dermatol Surg Oncol. 1984;10:873-875.
- Schwarze HP, Loche F, Lamant L, et al. Microcystic adnexal carcinoma induced by multiple radiation therapy. Int J Dermatol. 2000;39:369-372.
- Cooper PH, Mills SE. Microcystic adnexal carcinoma. J Am Acad Dermatol. 1984;10:908-914.
- Hamm JC, Argenta LC, Swanson NA. Microcystic adnexal carcinoma: an unpredictable aggressive neoplasm. Ann Plast Surg. 1987;19:173-180.
- Birkby CS, Argenyi ZB, Whitaker DC. Microcystic adnexal carcinoma with mandibular invasion and bone marrow replacement. J Dermatol Surg Oncol. 1989;15:308-312.
- Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:295-300.
- Gardner ES, Goldb
Syringomatous carcinoma (SC), considered by some to be a variant of microcystic adnexal carcinoma (MAC),1 is a rare malignant neoplasm of sweat gland origin. SC encompasses a range of neoplasms with different degrees of differentiation, and its nomenclature has varied over the years. SC also has been referred to as syringoid eccrine carcinoma,2 basal cell tumor with eccrine differentiation,3 malignant syringoma,4 and sclerosing sweat duct carcinoma.5 Its diagnosis has been a dilemma in a number of reported cases, probably due to the combination of its rarity and thus limited clinical and histopathologic information, microscopic similarities to other benign and malignant neoplasms, and characteristic histologic features that may only be apparent in surgical excisions containing deeper tissue. We report a case of SC that masqueraded as an epidermoid cyst in an unusually young patient.
Case Report
A 23-year-old Asian man, who was otherwise healthy, presented with an asymptomatic slowly enlarging nodule of one year's duration on the right medial eyebrow. Prior treatment with intralesional steroid injections resulted in minimal improvement. The patient had no personal or family history of skin cancers. Physical examination results demonstrated a well-demarcated, mobile, nontender subcutaneous nodule measuring 7 mm in diameter. The clinical presentation favored a diagnosis of an epidermal inclusion cyst, and the patient underwent surgical excision of the lesion. Results of the histopathologic examination revealed a neoplasm in the dermis consisting of bands and nests of pale staining basaloid cells extending between the collagen fibers (Figure 1). There were focal areas of ductal differentiation, scattered individual necrotic cells, moderate dermal fibrosis, and chronic inflammation with numerous eo-sinophils. Moderate nuclear atypia also was present (Figure 2). Perineural involvement was not seen. Results of immunohistochemical analysis revealed positive staining for high—and low—molecular-weight cytokeratins, as well as carcinoembryonic antigen (CEA)(Figure 3). There was scattered positivity with S-100 protein in occasional cells lining lumina and in dendritic cells (Figure 4). The histopathologic findings supported the diagnosis of SC. Because the neoplasm extended to the surgical margins of the specimen, repeat surgical excision with continuous microscopic control under the Mohs micrographic technique was performed to prevent local recurrence and spare normal tissue. At the 18-month follow-up visit, no local recurrence was seen.
Comment SC is a rare, malignant sweat gland neoplasm that usually occurs in the fourth and fifth decades of life.4-8 SC typically presents as a slow-growing, solitary, painless nodule or indurated plaque on the head or neck region.6-8 It has been frequently found on the upper and lower lips; however, it also has been reported to occur on the finger and breast.9,10 Predisposing factors for the development of SC are unclear11 but may include previous radiation to the face and history of receiving an organ transplant with immunosuppressive drug therapy.12-17 Histopathologically, SC is characterized by asymmetric and deep dermal invasion of tumor cells, perineural involvement, ductal formation, keratin-filled cysts, multiple nests of basaloid or squamous cells, and desmoplasia of the surrounding dermal stroma (Table 1).5,6 Some authors consider SC to be closely related to MAC but generally describe SC as more basaloid with larger tubules and a more sclerotic stroma than MAC.18-26 If histologic examination of SC is limited to the superficial dermis, SC demonstrates similarities to other neoplasms, including syringomas, trichoadenomas, trichoepitheliomas, basal cell carcinomas, or squamous cell carcinomas. In the reported cases in which SC was initially misdiagnosed as another benign or malignant neoplasm, many misdiagnoses were due to either a benign clinical appearance of the lesion or biopsy specimens that were too superficial to contain the deeper characteristic histologic features of SC.8,9,11,27-30
Immunohistochemical studies can facilitate the diagnosis of SC and differentiate it from other neoplasms. SC stains positively for CEA, S-100 protein, epithelial membrane antigen, cyto-keratin, and gross cystic disease fluid protein 15,31 all of which aid in the confirmation of a sweat gland neoplasm (Table 2).8,32,33,39 Positivity for CEA in the ductal lining cells and the luminal contents of tumor ducts confirms sweat gland differentiation.25,33,34 This ductal immunoreactivity to CEA appears to be one of the most reliable findings to differentiate SC and MAC from other adnexal tumors, especially desmoplastic trichoepithelioma, which may be one of the more challenging histo-pathologic differential diagnoses.35 In addition, epithelial membrane antigen positivity can be found in the areas showing glandular features.35 This can assist in distinguishing SC from a desmoplastic trichoepithelioma or sclerosing type basal cell carcinoma, both of which demonstrate negativity to epithelial membrane antigen.35 S-100 protein positivity in dendritic cells, as well as in some cords and ducts in SC, further verifies dendritic differentiation toward sweat gland structures and is useful as an adjunct in the confirmation of glandular differentiation.25,33,34,36
Without proper and timely diagnosis and management, SC can cause severe patient morbidity. Although SC rarely metastasizes and can have an indolent course, it can be locally de-structive and lead to potentially disfiguring outcomes.5-7 SC can invade deeply and infiltrate into the dermis, subcutaneous fat tissue, muscle, perichondrium, periosteum, and galea.8 Goto et al9 reported a case of an SC that was initially misdiagnosed as a basal cell carcinoma of the left middle finger. The deeper, characteristic features of SC were not recognized until after the affected finger required amputation due to erosion of the bone. Hoppenreijs et al11 described an aggressive case of an SC arising at a site of previously irradiated squamous cell carcinoma of the lower eyelid. Extensive involvement of the SC in the orbit led to the recommendation of an orbital exenter-ation; however, it was not performed because of the poor clinical condition of the patient. Treatments for SC have included wide local excision and Mohs micrographic surgery (MMS). SC treatment with wide local excision often resulted in incomplete excision of the neoplasm despite having taken an adequate margin around the clinically assessable tumor.5 Cases of SC treated with wide local excision had a recurrence rate of 47%.5 The positive surgical margins following wide local excision may be due to the deep infiltration of SC, which frequently exceeds the clinically predicted size of the tumor.5 Due to the close relationship of MAC and SC, we feel that MMS treatment of SC will reduce recurrences as it has for MAC. Currently, there is strong support for the treatment of MAC with MMS as a gold standard to ensure complete clearance of the neoplasm and to reduce the local recurrence rate.12,13,17,21,22,37,38 In a study of MAC by Chiller et al,37 the authors demonstrated a median 4-fold increase in defect size when they compared the clinically estimated pretreatment size of the lesion with the MMS-determined posttreatment size of the lesion. The authors therefore suggest that, similar to the MMS-treated lesions, the lesions completely treated with wide local excision also would produce a defect size that is at least 4 times greater than the predicted pretreatment size of the lesion. Because wide local excision relies on predicted margins of the lesion, which the authors have shown can be greatly underestimated, Chiller et al37 argue that the use of MMS, which does not rely on predicted margins, is a reasonable first-line therapeutic modality for effectively treating patients with MAC. Furthermore, MMS allows for the examination of the entire peripheral and deep margins of the lesion, which is critical when considering the deep infiltrative nature of MAC. The reported local recurrence rate of MAC treated with MMS is 0% to 5%,12,13,21,26,38 which is much lower than the reported local recurrence rate following treatment with wide local excision. This reduced recurrence rate found in MAC cases treated with MMS is probably due to the ability to confirm complete removal of the neoplasm with MMS.
Conclusion To our knowledge, this case report describes the occurrence of SC, a rare sweat gland neoplasm, in the youngest reported patient and is only the second reported case of SC treated with MMS. Adequate sampling of tissue with an excisional biopsy allowed for appropriate evaluation with histologic and immunohistochemical studies to arrive at the diagnosis that could easily have been missed with a superficial biopsy. In our patient, histopathologic evaluation showed typical nests of basaloid cells, ductal differentiation, and ductal fibrosis seen in SC. However, perineural involvement that is particularly characteristic of SC was not present. This may portend a better prognosis for our patient whose tumor was completely excised after one stage of MMS and has not shown evidence of recurrence at the 18-month follow-up visit. MMS allowed for evaluation of the entire surgical margin and decreased risk of local recurrence resulting from an incomplete excision. In addition, it also allowed for sparing of normal tissue in a cosmetically sensitive area where SC commonly occurs. In summary, this case highlights the importance of including SC in the differential diagnosis of an enlarging cystic lesion in a younger patient and its successful treatment with MMS.
Syringomatous carcinoma (SC), considered by some to be a variant of microcystic adnexal carcinoma (MAC),1 is a rare malignant neoplasm of sweat gland origin. SC encompasses a range of neoplasms with different degrees of differentiation, and its nomenclature has varied over the years. SC also has been referred to as syringoid eccrine carcinoma,2 basal cell tumor with eccrine differentiation,3 malignant syringoma,4 and sclerosing sweat duct carcinoma.5 Its diagnosis has been a dilemma in a number of reported cases, probably due to the combination of its rarity and thus limited clinical and histopathologic information, microscopic similarities to other benign and malignant neoplasms, and characteristic histologic features that may only be apparent in surgical excisions containing deeper tissue. We report a case of SC that masqueraded as an epidermoid cyst in an unusually young patient.
Case Report
A 23-year-old Asian man, who was otherwise healthy, presented with an asymptomatic slowly enlarging nodule of one year's duration on the right medial eyebrow. Prior treatment with intralesional steroid injections resulted in minimal improvement. The patient had no personal or family history of skin cancers. Physical examination results demonstrated a well-demarcated, mobile, nontender subcutaneous nodule measuring 7 mm in diameter. The clinical presentation favored a diagnosis of an epidermal inclusion cyst, and the patient underwent surgical excision of the lesion. Results of the histopathologic examination revealed a neoplasm in the dermis consisting of bands and nests of pale staining basaloid cells extending between the collagen fibers (Figure 1). There were focal areas of ductal differentiation, scattered individual necrotic cells, moderate dermal fibrosis, and chronic inflammation with numerous eo-sinophils. Moderate nuclear atypia also was present (Figure 2). Perineural involvement was not seen. Results of immunohistochemical analysis revealed positive staining for high—and low—molecular-weight cytokeratins, as well as carcinoembryonic antigen (CEA)(Figure 3). There was scattered positivity with S-100 protein in occasional cells lining lumina and in dendritic cells (Figure 4). The histopathologic findings supported the diagnosis of SC. Because the neoplasm extended to the surgical margins of the specimen, repeat surgical excision with continuous microscopic control under the Mohs micrographic technique was performed to prevent local recurrence and spare normal tissue. At the 18-month follow-up visit, no local recurrence was seen.
Comment SC is a rare, malignant sweat gland neoplasm that usually occurs in the fourth and fifth decades of life.4-8 SC typically presents as a slow-growing, solitary, painless nodule or indurated plaque on the head or neck region.6-8 It has been frequently found on the upper and lower lips; however, it also has been reported to occur on the finger and breast.9,10 Predisposing factors for the development of SC are unclear11 but may include previous radiation to the face and history of receiving an organ transplant with immunosuppressive drug therapy.12-17 Histopathologically, SC is characterized by asymmetric and deep dermal invasion of tumor cells, perineural involvement, ductal formation, keratin-filled cysts, multiple nests of basaloid or squamous cells, and desmoplasia of the surrounding dermal stroma (Table 1).5,6 Some authors consider SC to be closely related to MAC but generally describe SC as more basaloid with larger tubules and a more sclerotic stroma than MAC.18-26 If histologic examination of SC is limited to the superficial dermis, SC demonstrates similarities to other neoplasms, including syringomas, trichoadenomas, trichoepitheliomas, basal cell carcinomas, or squamous cell carcinomas. In the reported cases in which SC was initially misdiagnosed as another benign or malignant neoplasm, many misdiagnoses were due to either a benign clinical appearance of the lesion or biopsy specimens that were too superficial to contain the deeper characteristic histologic features of SC.8,9,11,27-30
Immunohistochemical studies can facilitate the diagnosis of SC and differentiate it from other neoplasms. SC stains positively for CEA, S-100 protein, epithelial membrane antigen, cyto-keratin, and gross cystic disease fluid protein 15,31 all of which aid in the confirmation of a sweat gland neoplasm (Table 2).8,32,33,39 Positivity for CEA in the ductal lining cells and the luminal contents of tumor ducts confirms sweat gland differentiation.25,33,34 This ductal immunoreactivity to CEA appears to be one of the most reliable findings to differentiate SC and MAC from other adnexal tumors, especially desmoplastic trichoepithelioma, which may be one of the more challenging histo-pathologic differential diagnoses.35 In addition, epithelial membrane antigen positivity can be found in the areas showing glandular features.35 This can assist in distinguishing SC from a desmoplastic trichoepithelioma or sclerosing type basal cell carcinoma, both of which demonstrate negativity to epithelial membrane antigen.35 S-100 protein positivity in dendritic cells, as well as in some cords and ducts in SC, further verifies dendritic differentiation toward sweat gland structures and is useful as an adjunct in the confirmation of glandular differentiation.25,33,34,36
Without proper and timely diagnosis and management, SC can cause severe patient morbidity. Although SC rarely metastasizes and can have an indolent course, it can be locally de-structive and lead to potentially disfiguring outcomes.5-7 SC can invade deeply and infiltrate into the dermis, subcutaneous fat tissue, muscle, perichondrium, periosteum, and galea.8 Goto et al9 reported a case of an SC that was initially misdiagnosed as a basal cell carcinoma of the left middle finger. The deeper, characteristic features of SC were not recognized until after the affected finger required amputation due to erosion of the bone. Hoppenreijs et al11 described an aggressive case of an SC arising at a site of previously irradiated squamous cell carcinoma of the lower eyelid. Extensive involvement of the SC in the orbit led to the recommendation of an orbital exenter-ation; however, it was not performed because of the poor clinical condition of the patient. Treatments for SC have included wide local excision and Mohs micrographic surgery (MMS). SC treatment with wide local excision often resulted in incomplete excision of the neoplasm despite having taken an adequate margin around the clinically assessable tumor.5 Cases of SC treated with wide local excision had a recurrence rate of 47%.5 The positive surgical margins following wide local excision may be due to the deep infiltration of SC, which frequently exceeds the clinically predicted size of the tumor.5 Due to the close relationship of MAC and SC, we feel that MMS treatment of SC will reduce recurrences as it has for MAC. Currently, there is strong support for the treatment of MAC with MMS as a gold standard to ensure complete clearance of the neoplasm and to reduce the local recurrence rate.12,13,17,21,22,37,38 In a study of MAC by Chiller et al,37 the authors demonstrated a median 4-fold increase in defect size when they compared the clinically estimated pretreatment size of the lesion with the MMS-determined posttreatment size of the lesion. The authors therefore suggest that, similar to the MMS-treated lesions, the lesions completely treated with wide local excision also would produce a defect size that is at least 4 times greater than the predicted pretreatment size of the lesion. Because wide local excision relies on predicted margins of the lesion, which the authors have shown can be greatly underestimated, Chiller et al37 argue that the use of MMS, which does not rely on predicted margins, is a reasonable first-line therapeutic modality for effectively treating patients with MAC. Furthermore, MMS allows for the examination of the entire peripheral and deep margins of the lesion, which is critical when considering the deep infiltrative nature of MAC. The reported local recurrence rate of MAC treated with MMS is 0% to 5%,12,13,21,26,38 which is much lower than the reported local recurrence rate following treatment with wide local excision. This reduced recurrence rate found in MAC cases treated with MMS is probably due to the ability to confirm complete removal of the neoplasm with MMS.
Conclusion To our knowledge, this case report describes the occurrence of SC, a rare sweat gland neoplasm, in the youngest reported patient and is only the second reported case of SC treated with MMS. Adequate sampling of tissue with an excisional biopsy allowed for appropriate evaluation with histologic and immunohistochemical studies to arrive at the diagnosis that could easily have been missed with a superficial biopsy. In our patient, histopathologic evaluation showed typical nests of basaloid cells, ductal differentiation, and ductal fibrosis seen in SC. However, perineural involvement that is particularly characteristic of SC was not present. This may portend a better prognosis for our patient whose tumor was completely excised after one stage of MMS and has not shown evidence of recurrence at the 18-month follow-up visit. MMS allowed for evaluation of the entire surgical margin and decreased risk of local recurrence resulting from an incomplete excision. In addition, it also allowed for sparing of normal tissue in a cosmetically sensitive area where SC commonly occurs. In summary, this case highlights the importance of including SC in the differential diagnosis of an enlarging cystic lesion in a younger patient and its successful treatment with MMS.
- Weedon D. Tumors of cutaneous appendages. In: Weedon D, ed. Skin Pathology. 2nd ed. London, England: Churchill Livingstone; 2002:897.
- Sanchez Yus E, Requena Caballero L, Garcia Salazar I, et al. Clear cell syringoid eccrine carcinoma. Am J Dermatopathol. 1987;9:225-231.
- Freeman RG, Winkelmann RK. Basal cell tumor with eccrine differentiation (eccrine epithelioma). Arch Dermatol. 1969;100:234-242.
- Glatt HJ, Proia AD, Tsoy EA, et al. Malignant syringoma of the eyelid. Ophthalmology. 1984;91:987-990.
- Cooper PH, Mills SE, Leonard DD, et al. Sclerosing sweat duct (syringomatous) carcinoma. Am J Surg Pathol. 1985;9:422-433.
- Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: a clinicopathologic study of 35 cases. Arch Dermatol. 1983;119:104-114.
- Wick MR, Goellner JR, Wolfe JT III, et al. Adnexal carcinomas of the skin, I: eccrine carcinomas. Cancer. 1985;56:1147-1162.
- Abenoza P, Ackerman AB. Syringomatous carcinomas. In: Abenoza P, Ackerman AB, eds. Neoplasms with Eccrine Differentiation. Philadelphia, Pa: Lea & Febiger; 1990:371-412.
- Goto M, Sonoda T, Shibuya H, et al. Digital syringomatous carcinoma mimicking basal cell carcinoma. Br J Dermatol. 2001;144:438-439.
- Urso C. Syringomatous breast carcinoma and correlated lesions. Pathologica. 1996;88:196-199.
- Hoppenreijs VP, Reuser TT, Mooy CM, et al. Syringomatous carcinoma of the eyelid and orbit: a clinical and histopathological challenge. Br J Ophthalmol. 1997;81:668-672.
- Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27:401-408.
- Friedman PM, Friedman RH, Jiang SB, et al. Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol. 1999;41:225-231.
- Antley CA, Carney M, Smoller BR. Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. J Cutan Pathol. 1999;26:48-50.
- Borenstein A, Seidman DS, Trau H, et al. Microcystic adnexal carcinoma following radiotherapy in childhood. Am J Med Sci. 1991;301:259-261.
- Fleischmann HE, Roth RJ, Wood C, et al. Microcystic adnexal carcinoma treated by microscopically controlled excision. J Dermatol Surg Oncol. 1984;10:873-875.
- Schwarze HP, Loche F, Lamant L, et al. Microcystic adnexal carcinoma induced by multiple radiation therapy. Int J Dermatol. 2000;39:369-372.
- Cooper PH, Mills SE. Microcystic adnexal carcinoma. J Am Acad Dermatol. 1984;10:908-914.
- Hamm JC, Argenta LC, Swanson NA. Microcystic adnexal carcinoma: an unpredictable aggressive neoplasm. Ann Plast Surg. 1987;19:173-180.
- Birkby CS, Argenyi ZB, Whitaker DC. Microcystic adnexal carcinoma with mandibular invasion and bone marrow replacement. J Dermatol Surg Oncol. 1989;15:308-312.
- Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:295-300.
- Gardner ES, Goldb
- Weedon D. Tumors of cutaneous appendages. In: Weedon D, ed. Skin Pathology. 2nd ed. London, England: Churchill Livingstone; 2002:897.
- Sanchez Yus E, Requena Caballero L, Garcia Salazar I, et al. Clear cell syringoid eccrine carcinoma. Am J Dermatopathol. 1987;9:225-231.
- Freeman RG, Winkelmann RK. Basal cell tumor with eccrine differentiation (eccrine epithelioma). Arch Dermatol. 1969;100:234-242.
- Glatt HJ, Proia AD, Tsoy EA, et al. Malignant syringoma of the eyelid. Ophthalmology. 1984;91:987-990.
- Cooper PH, Mills SE, Leonard DD, et al. Sclerosing sweat duct (syringomatous) carcinoma. Am J Surg Pathol. 1985;9:422-433.
- Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: a clinicopathologic study of 35 cases. Arch Dermatol. 1983;119:104-114.
- Wick MR, Goellner JR, Wolfe JT III, et al. Adnexal carcinomas of the skin, I: eccrine carcinomas. Cancer. 1985;56:1147-1162.
- Abenoza P, Ackerman AB. Syringomatous carcinomas. In: Abenoza P, Ackerman AB, eds. Neoplasms with Eccrine Differentiation. Philadelphia, Pa: Lea & Febiger; 1990:371-412.
- Goto M, Sonoda T, Shibuya H, et al. Digital syringomatous carcinoma mimicking basal cell carcinoma. Br J Dermatol. 2001;144:438-439.
- Urso C. Syringomatous breast carcinoma and correlated lesions. Pathologica. 1996;88:196-199.
- Hoppenreijs VP, Reuser TT, Mooy CM, et al. Syringomatous carcinoma of the eyelid and orbit: a clinical and histopathological challenge. Br J Ophthalmol. 1997;81:668-672.
- Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27:401-408.
- Friedman PM, Friedman RH, Jiang SB, et al. Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol. 1999;41:225-231.
- Antley CA, Carney M, Smoller BR. Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. J Cutan Pathol. 1999;26:48-50.
- Borenstein A, Seidman DS, Trau H, et al. Microcystic adnexal carcinoma following radiotherapy in childhood. Am J Med Sci. 1991;301:259-261.
- Fleischmann HE, Roth RJ, Wood C, et al. Microcystic adnexal carcinoma treated by microscopically controlled excision. J Dermatol Surg Oncol. 1984;10:873-875.
- Schwarze HP, Loche F, Lamant L, et al. Microcystic adnexal carcinoma induced by multiple radiation therapy. Int J Dermatol. 2000;39:369-372.
- Cooper PH, Mills SE. Microcystic adnexal carcinoma. J Am Acad Dermatol. 1984;10:908-914.
- Hamm JC, Argenta LC, Swanson NA. Microcystic adnexal carcinoma: an unpredictable aggressive neoplasm. Ann Plast Surg. 1987;19:173-180.
- Birkby CS, Argenyi ZB, Whitaker DC. Microcystic adnexal carcinoma with mandibular invasion and bone marrow replacement. J Dermatol Surg Oncol. 1989;15:308-312.
- Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:295-300.
- Gardner ES, Goldb